Integer Holdings (ITGR)
(Real Time Quote from BATS)
$127.22 USD
+1.05 (0.83%)
Updated Sep 13, 2024 03:54 PM ET
After-Market: $126.86 -0.36 (-0.28%) 4:18 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$127.22 USD
+1.05 (0.83%)
Updated Sep 13, 2024 03:54 PM ET
After-Market: $126.86 -0.36 (-0.28%) 4:18 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.
Allscripts (MDRX) Inches Up 0.3% on Earnings Beat in Q1
by Zacks Equity Research
Allscripts (MDRX) witnesses a year- over- year surge in earnings during Q1.
Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.
PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.
Integer (ITGR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Integer (ITGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.
Integer (ITGR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 12.79% and 2.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integer (ITGR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE
by Zacks Equity Research
Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Integer (ITGR) Up 7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.
Boston Scientific's (BSX) DBS System Gets FDA's Clearance
by Zacks Equity Research
The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Here's Why You Should Avoid Betting on Integer Holdings (ITGR)
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational third-quarter 2020 performance weighs on Integer Holdings (ITGR).
Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.
Integer (ITGR) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 56.25% and 2.72%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integer (ITGR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Avoid Betting on Integer Holdings Now
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational performance weighs on Integer Holdings (ITGR).
Integer (ITGR) Up 2.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.
Integer (ITGR) Q2 Earnings Miss Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -20.00% and 1.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integer (ITGR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Integer Holdings Stock for Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.